Muangman Pornprom, Chuntrasakul Chomchark, Silthram Soranit, Suvanchote Supaporn, Benjathanung Rachanee, Kittidacha Suchada, Rueksomtawin Somphon
Burn Unit, Trauma Division, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
J Med Assoc Thai. 2006 Jul;89(7):953-8.
Acticoat (Smith & Nephew, Hull, UK) is a silver-coated dressing reported to reduce infection and exhibit antimicrobial activity in wounds.
The purpose of the present study was to compare the efficacy ofacticoat and 1% silver sulfadiazine (1% AgSD) for treatment of partial thickness burn wounds.
The authors reviewed 50 patients who had partial thickness burn wounds less than 25% admitted to Siriraj Burn Unit from May 2002 to September 2005. All patients were divided into 2 groups: the acticoat treated group (25 patients) and the 1% silver sulfadiazine treated group (25 patients). The 2 groups were compared for the etiology of burn wound, demographic data including age, sex, % Total Body Surface Area burn (TBSA%), cultured organisms, wound infection and outcome of Length Of hospital Stay (LOS) and level of pain.
The authors found no significant differences in age, TBSA (%) between both groups. 7 patients (28%) developed wound infection. There were no differences in wound infection and LOS between both groups (p > 0.05). All of the patients who developed wound infection responded well to targeted topical and systemic antibiotic treatment. The 1% AgSD treated group (6 of 25, 24%) obtained more split thickness skin graft to close the granulation defects compared to patients who were treated with acticoat (4 of 25, 16%) but no statistical significance, p = 0.32). Average pain scores in the acticoat treated groups were significantly lower than the 1% AgSD treated group (4 +/- 0.6 versus 5 +/- 0.7, respectively).
The present study confirms the efficacy of acticoat treatment in partial thickness burn wound. The authors conclude that acticoat has an advantage of limiting the frequency of replacement of the dressing and provides a less painful alternative to wound care with 1% AgSD with comparable incidence of burn wound infection. This is due to its long wear time and the ease of application and removal.
Acticoat(施乐辉公司,英国赫尔)是一种镀银敷料,据报道可减少伤口感染并具有抗菌活性。
本研究旨在比较Acticoat与1%磺胺嘧啶银(1% AgSD)治疗浅Ⅱ度烧伤创面的疗效。
作者回顾了2002年5月至2005年9月入住诗里拉吉烧伤科的50例浅Ⅱ度烧伤面积小于25%的患者。所有患者分为两组:Acticoat治疗组(25例)和1%磺胺嘧啶银治疗组(25例)。比较两组烧伤创面的病因、人口统计学数据(包括年龄、性别、烧伤总面积百分比(TBSA%))、培养出的微生物、伤口感染情况以及住院时间(LOS)和疼痛程度等结果。
作者发现两组在年龄、TBSA(%)方面无显著差异。7例患者(28%)发生伤口感染。两组在伤口感染和住院时间方面无差异(p>0.05)。所有发生伤口感染的患者对针对性的局部和全身抗生素治疗反应良好。与Acticoat治疗的患者(25例中的4例,16%)相比,1% AgSD治疗组(25例中的6例,24%)进行了更多的中厚皮片移植以闭合肉芽创面缺损,但无统计学意义(p = 0.32)。Acticoat治疗组的平均疼痛评分显著低于1% AgSD治疗组(分别为4±0.6和5±0.7)。
本研究证实了Acticoat治疗浅Ⅱ度烧伤创面的疗效。作者得出结论,Acticoat具有减少换药频率的优势,并且在烧伤创面感染发生率相当的情况下,与1% AgSD相比,为伤口护理提供了一种疼痛较轻的选择。这归因于其较长的佩戴时间以及易于应用和去除的特点。